. Author manuscript; available in PMC: 2016 Jul 1.

Published in final edited form as: Pediatr Blood Cancer. 2015 Mar 2;62(7):1171–1175. doi: 10.1002/pbc.25454

Table III.

Common Grade 3/4 Non-Hematologic Toxicities

Toxicity	B1 Cohort (weekly × 4) (n=54)	B2 Cohort (twice weekly × 8) (n=60)	B1 and B2 Cohorts (n=114)	AALL01P2^* (n=63)	P-value^**
Infection (documented clinically or microbiologically)	35 (64.8%)	22 (36.7%)	57 (50.0%)	21 (33.3%)	0.0233
Febrile neutropenia	9 (16.7%)	21 (35%)	30 (26.3%)	28 (44.4%)	0.0114
Hyperglycemia	17 (31.5)	11(18.3%)	28 (24.6%)	7 (11.1%)	0.0227
ALT elevation	4 (7.4%)	7 (11.7%)	11 (9.6%)	12 (19.0%)	0.0629
Pancreatitis	6 (11.1%)	1 (1.7%)	7 (6.1%)	4 (6.3%)	0.5953

Analysis limited to the 63 patients on AALL01P2 with early marrow B-lineage relapses;

^**

One-sided P-values are provided for comparisons of toxicites in the B1 and B2 cohorts combined vs. AALL01P2.